We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Developed for Rapid Leptospirosis Diagnosis

By LabMedica International staff writers
Posted on 13 Nov 2012
Print article
A rapid assay has been developed using immunodominant Leptospira immunoglobulin-like proteins in a Dual Path Platform (DPP) for the diagnosis of leptospirosis.

The rapid point-of-care immunoassay was evaluated for accuracy in diagnostic performance and compared with the microscopic agglutination test (MAT), in an urban setting.

Scientists at Duke University School of Medicine (Durham, NC, USA) and their collaborators measured the sensitivity of the assay using 446 serum samples from 378 individuals with either mild or severe leptospirosis from two urban Brazilian populations. Control sera, including healthy blood donors, dengue cases, and patients with confirmed syphilis were also tested.

The DPP assay for leptospirosis was developed by Chembio Diagnostic Systems (Medford, NY, USA) and is manufactured by Bio-Manguinhos (Rio de Janeiro, Brazil). The sera assayed by the DPP were also tested by an immunoglobulin M enzyme-linked immunosorbent assay (IgM- ELISA) and the MAT. Three independent operators visually interpreted results of the DPP after 20 minutes as either positive or negative.

The overall sensitivity for paired sera was 100% for severe and 73% for mild disease. In the acute phase of the infection, the assay achieved a sensitivity of 85% for severe and 64% for mild leptospirosis. Within seven days of illness onset, the assay achieved a sensitivity of 77% for severe disease and 60% for mild leptospirosis. Sensitivity of the DPP assay was similar to that for IgM-ELISA and increased with both duration of symptoms.

The authors concluded that the DPP assay performed acceptably well for diagnosis of severe acute clinical leptospirosis and can be easily implemented in hospitals and health posts where leptospirosis is a major public health problem. However, test accuracy may need improvement for mild disease and early stage leptospirosis, particularly in regions with high transmission. The study was published on November 1, 2012, in the journal Public Library of Science Neglected Tropical Diseases (PLoSNTD).

Related Links:

Duke University School of Medicine
Chembio Diagnostic Systems
Bio-Manguinhos


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.